logo
‘Cult' of tourniquets causing thousands of unnecessary amputations and deaths in Ukraine, say surgeons

‘Cult' of tourniquets causing thousands of unnecessary amputations and deaths in Ukraine, say surgeons

Yahoo16 hours ago
The tourniquet has saved many thousands of lives and limbs in war zones around the world, but misuse of the device is causing huge numbers of excess amputations and deaths in Ukraine, say top military surgeons.
Captain Rom A Stevens, a retired senior US medical navy officer who has served in Iraq, Afghanistan, and East Africa, estimates that of the roughly 100,000 amputations performed on Ukrainian soldiers since Russia's full-scale invasion in 2022, as many as 75,000 were caused by improper use of tourniquets.
'I've seen tourniquets that have been left on for days, often for injuries that could have been stopped by other methods. Then [the patient] has to have their limb amputated because the tissue has died,' Captain Stevens told The Telegraph.
Tourniquets are strong bands used to stop catastrophic bleeding by cutting off blood flow, and are standard issue for most modern armies.
But if left on over two hours, they can cause tissue death, meaning the arm or leg which has the tourniquet on is no longer viable and requires amputation.
The device became standard-issue in the 2000s wars in Iraq and Afghanistan, where rapid air evacuation to military surgical teams was possible in under 60 minutes. If the tourniquet was unnecessary it was removed, and no harm was done.
But in Ukraine, where the skies are infested with drones, injured soldiers are evacuated by land, often far exceeding the safe time window for tourniquet use.
This critical delay has caused tens of thousands of amputations, say experts, many of which were unnecessary because the injuries didn't require a tourniquet in the first place.
It has also led to a sharp rise in young Ukrainians needing dialysis, said Captain Stevens who has served as a medical volunteer in hospitals in Zaporizhzhiya, Dnipro, and L'viv since the invasion in 2022.
This is because when a tourniquet is removed after being kept on too long, toxins from dead tissue flood the bloodstream, overwhelming the kidneys.
Captain Stevens helped draft the US military guidelines for tourniquet use and now wishes greater emphasis had been placed on assessing when they were needed to stop bleeding.
He fears that their successful use in wars where rapid evacuation was possible has led to a 'cult-like' dependence on a tool that should be used much more sparingly.
In Ukraine, it has left 'a generation of men traumatised by unnecessary amputations,' he said.
The US Tactical Combat Casualty Care (TCCC) handbook was created for trained military medics operating in war zones in the 1990s and heavily promotes the use of tourniquets in war, describing their use as 'the best method to control life-threatening bleeding'.
Widely adopted by NATO and Western armed forces in the early 2000s, the TCCC standards were quickly integrated into Ukrainian military and civilian medical training following the Russian invasion of Crimea in 2014.
Captain Stevens – though an author of the TCCC – says this was a error.
'If you have a perfect battlefield, then tourniquets work. But if you don't – if you have a situation like Ukraine today – you can end up with a tragedy. And that's what the Ukrainians have,' he said.
'There's now hundreds of thousands of tourniquets that have been distributed to military forces, civilians, fire departments, and police in Ukraine. It's become a cult, and because it saved lives in Iraq and Afghanistan, people think it's a good idea,' he added.
While most Western militaries embed specialist medics in every unit, Ukraine's armed forces – made up largely of conscripts and civilian volunteers – often rely on medics with only a few weeks or even days of training who are often unable to distinguish between injuries that do and don't require tourniquets.
'The Ukrainian infantry and artillery battalions are undermanned. They can't replace their medics when they get injured or killed,' Captain Stevens said.
A 2022 study by a Ukrainian military vascular surgeon, Dr Vladyslav Yatsun, found that only 24.6 per cent of war wounded patients arriving at hospital with tourniquets had injuries that justified their use to stop bleeding.
'In all other cases, the use of pressure bandages was more appropriate,' the study said.
They are also often being applied too high on damaged limbs, said Captain Stevens. 'They are often taught to place on the tourniquets well above the wounds, and the result is a very high amputation, making it difficult to later fit a prosthesis,' he said.
An updated version of the Ukrainian TCCC disseminated to the armed forces in January 2024 specifically reads: 'Place the tourniquet 'high and tight' on the wounded extremity.'
NATO has also raised concerns about tourniquets in Ukraine.
Last year, the agency dispatched a team of medical and military experts to investigate what it described as 'an unacceptable high complication rate from the use of tourniquets [...] resulting in amputations, renal failure and even death.'
The organisation added: 'The current situation with prolonged evacuation times requires a shift in attitude towards tourniquets,' although it has yet to formally publish its recommendations.
Experts stress that tourniquets continue to save many lives and should not be abandoned.
Instead, they say that in places like Ukraine where rapid evacuation is difficult they should only be used in the three circumstances in which they are absolutely necessary.
The first is when a limb has been completely severed. 'In that situation, you need a tourniquet, but you need to put it as low down as possible to try and save as much of the limb as you can,' said Captain Stevens.
The second is when the limb is so damaged that it cannot be saved – a decision that requires judgement and medical experience.The third is when a person has uncontrolled arterial bleeding that cannot be stopped with direct pressure or any other method.
Captain Stevens said tourniquets are often applied by panicked soldiers, who lack the knowledge or confidence to try other methods first.
'When a [Ukrainian] soldier is injured in the field, they're usually taken care of by other soldiers in a panic,' he said. 'They see blood. They put on tourniquets because they have tourniquets. We gave them tourniquets.'
Dr Ostap Zubach, an orthopaedic surgeon who works at a major trauma hospital in L'viv, agrees that while tourniquets can be life-saving, they can also be deadly when used incorrectly.
'As a doctor, I believe that in the right hands, tourniquets are a brilliant thing. But in the wrong hands, they can be very dangerous,' he said.
A particular problem was that many soldiers did not know how to temporarily loosen a tourniquet periodically to extend the time of safe use.
'The strategy of tourniquets [in Ukraine] is just not working, especially when [the soldiers] don't know how to convert them,' said Dr Zubach. 'Many of our soldiers have no experience in the military or medicine.'
Major General Anatoliy Petrovych Kazmirchuk, Commander of the Medical Forces of the Ukrainian Army, introduced tourniquet 'conversion' into the basic military training programme last year following reports of excessive amputations and limb loss at the front.
But both Captain Stevens and Dr Zubach are sceptical on what impact the new training is having.
'The problem is that under fire, people are afraid to take the tourniquets down. They're in a rush to get that patient to a hospital surgeon and don't stop to convert them,' said Captain Stevens.
A growing group of medics both in and outside of Ukraine are now putting pressure on the ministry of defence to move away from the TCCC handbook and develop their own set of medical guidelines for use in the Ukrainian context, factoring in long evacuation times.
'Guidelines are only guidelines. They require common sense to apply, they require professional judgement. In Ukraine, they don't have a system for developing guidelines. Often they just take Western, US, British, NATO guidelines, and translate them, word for word into Ukrainian,' said Captain Stevens.
'But there's a lot of resistance to changing it. The Ukrainians are taking their cue from the Americans, but our protocols were not designed for this situation,' he added.
'If you go back to World War Two and you read what the American theatre surgeons had to say about tourniquets, they said they were dangerous because they were often placed on wounds that did not require them, and then not taken off before it was too late,' he said.
'You didn't have a rapid evacuation there either. You're evacuating by land, over bumpy roads, in the middle of the night under fire, just like what the Ukrainians are doing now.'
Both Dr Zubach and Captain Stevens say more emphasis needs to be put on basic casualty care, like cutting off clothes to examine the wound to see the source of bleeding, use of pressure bandages, and alginates – jelly-like dressings that can absorb heavy bleeding and pack into wounds without the long-term risks associated with a tourniquet.
Both agree that tourniquets should be used only as a last resort, when all else has failed. 'Soldiers and medics need to understand that when a tourniquet is placed on the Ukrainian battlefield, it usually means an amputated limb,' says Stevens.
Protect yourself and your family by learning more about Global Health Security
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Hims & Hers Health Inc (HIMS) Q2 2025 Earnings Call Highlights: Robust Revenue Growth Amid ...
Hims & Hers Health Inc (HIMS) Q2 2025 Earnings Call Highlights: Robust Revenue Growth Amid ...

Yahoo

time22 minutes ago

  • Yahoo

Hims & Hers Health Inc (HIMS) Q2 2025 Earnings Call Highlights: Robust Revenue Growth Amid ...

Revenue: $545 million, a 73% year-over-year increase. Adjusted EBITDA Margin: Over 15%. Subscribers: Increased by 73,000 quarter over quarter to over 2.4 million, a 31% year-over-year growth rate. Monthly Average Revenue per Subscriber: Declined quarter over quarter to $74 from $84. Gross Margin: Expanded 3 points quarter over quarter to 76%. Cash and Short-term Investments: Over $1.1 billion at the end of the second quarter. Free Cash Flow: Negative $69 million for the second quarter. Third Quarter Revenue Guidance: Expected between $570 million to $590 million. Full Year Revenue Guidance: Expected between $2.3 billion and $2.4 billion. Full Year Adjusted EBITDA Guidance: Expected between $295 million to $335 million. Warning! GuruFocus has detected 5 Warning Sign with HIMS. Release Date: August 04, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Hims & Hers Health Inc (NYSE:HIMS) reported a 73% year-over-year revenue growth to $545 million in Q2 2025, with an adjusted EBITDA margin exceeding 15%. The company is expanding its platform with new specialties, including hormonal health, which is expected to address significant health issues for both men and women. Hims & Hers Health Inc (NYSE:HIMS) successfully acquired ZAVA, enhancing its presence in the UK and establishing a foundation for further expansion in Europe and Canada. The company is investing in AI and technology to enhance personalized care, aiming to provide 24/7 support and improve patient engagement. Hims & Hers Health Inc (NYSE:HIMS) plans to offer lab testing as a standalone service, which is expected to empower customers with better health insights and proactive health management. Negative Points The company faced headwinds from off-boarding GLP-1 subscribers on commercially available dosages, impacting revenue recognition. There is a decline in the on-demand sexual health subscriber base, which is expected to continue affecting revenue in the short term. Hims & Hers Health Inc (NYSE:HIMS) reported a negative free cash flow of $69 million in Q2 2025 due to significant investments in inventory and working capital. The transition towards more premium daily offerings in the sexual health segment is causing temporary revenue declines. The company anticipates increased marketing and technology investments, which may pressure margins in the near term. Q & A Highlights Q: Why was now the right time to expand internationally, and what made ZAVA the right company to acquire? A: Andrew Dudum, CEO, explained that the acquisition of ZAVA is a strategic move to replicate Hims & Hers' personalized, high-touch, affordable precision medicine model in key international markets. ZAVA's ability to scale in unique regulatory environments was a key factor in the acquisition. The international market is seen as a focused effort, with a multibillion-dollar revenue opportunity in a few key markets. Q: How does the launch of at-home lab testing improve the business and support the broader mission of Hims & Hers? A: Andrew Dudum, CEO, emphasized that at-home lab testing is foundational for transitioning healthcare from treatment to prevention. It simplifies necessary tests, makes them affordable, and educates patients on optimal health metrics. This initiative is expected to open membership opportunities similar to Amazon or Costco, focusing on preventative health. Q: Can you provide insights into the core business dynamics and expectations for Q3, especially regarding the personalized GLP-1 offering? A: Oluyemi Okupe, CFO, noted material headwinds in the GLP-1 segment due to off-boarding commercially available dosages. The core business is experiencing a drag from the sexual health on-demand segment, but specialties like dermatology and weight loss are growing robustly. The transition to daily offerings in sexual health is expected to improve retention and customer lifetime value. Q: What are the expectations for the Canadian expansion and the impact of generic semaglutide pricing? A: Andrew Dudum, CEO, stated that the Canadian expansion will leverage ZAVA's expertise, with offerings under the Hims & Hers brand. The generic semaglutide is expected to be priced significantly lower than branded options, unlocking substantial market access in Canada, where a large portion of the population is affected by weight issues. Q: How is the Hers business performing, and what are the key growth drivers? A: Oluyemi Okupe, CFO, reported robust growth in the Hers business, driven by dermatology, weight loss, and mental health offerings. The upcoming launch of hormonal support for menopause is expected to further catalyze growth. Q: What is the approach to AI investments, and what impact is expected on the business? A: Andrew Dudum, CEO, highlighted a strategy focused on immediate, tactical improvements through AI. The platform's extensive patient interactions allow for rapid deployment of AI use cases, aiming to enhance efficiency and engagement across the provider, patient, and pharmacist interfaces within 3 to 6 months. Q: Can you discuss the marketing strategy and patient acquisition costs for the second half of the year? A: Oluyemi Okupe, CFO, stated that marketing investments will be robust but adhere to a capital allocation framework with a payback period of less than a year. The focus will be on specialty-specific investments and talent acquisition to support new specialties and international expansion. Q: What are the expectations for inventory levels and supply chain management? A: Oluyemi Okupe, CFO, explained that inventory levels increased to ensure a durable supply for new specialties and to leverage the strong balance sheet amid global uncertainties. This is seen as an anomaly, with future inventory adjustments expected to stabilize. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Sign in to access your portfolio

High Lp(a) Signals Risk Beyond The Coronaries
High Lp(a) Signals Risk Beyond The Coronaries

Medscape

time23 minutes ago

  • Medscape

High Lp(a) Signals Risk Beyond The Coronaries

TOPLINE: Elevated levels of lipoprotein(a) [Lp(a)] were associated with significantly increased risks for incident peripheral artery disease and carotid artery stenosis. Among patients with peripheral artery disease, those with high levels of Lp(a) (≥ 150 nmol/L) had a high risk of progressing to major adverse limb events. METHODOLOGY: Despite lifestyle interventions and therapies for lowering levels of cholesterol, a residual risk for major atherosclerotic complication persists. Researchers analyzed data from a large prospective biobank (2006-2010) to investigate whether baseline levels of Lp(a) predict the risk for onset and progression of extracoronary athero­sclerotic vascular disease — a combination of peripheral artery disease and carotid artery stenosis. The UK biobank data included 460,544 individuals (average age at enrollment, 57 years; 54.2% men; 94.9% European) and followed them for a median duration of 13.6 years. Data on baseline serum levels of Lp(a) were retrieved, with levels ≥ 150 nmol/L (about 70 mg/dL) defined as high. The analysis assessed the incidence of peripheral artery disease and carotid artery stenosis and the progression to both the first major adverse limb event and first stroke. TAKEAWAY: Individuals with high levels of Lp(a) were older and more often men than those with normal levels of Lp(a) (P < .001 for both). Each 75-nmol/L (35 mg/dL) increase in levels of Lp(a) was associated with a 1.18-fold elevated risk for incident peripheral artery disease and a 1.17-fold increased risk for incident carotid artery stenosis (P < .0001 for both). Among patients with peripheral artery disease, those with high levels of Lp(a) had a 1.6-fold higher risk of developing major adverse limb events than those with normal levels of Lp(a) (P = .004). IN PRACTICE: 'Participants with established atherosclerotic vascular disease and elevated Lp(a) concentrations may represent the ideal group to benefit from targeted preventive interventions,' the researchers noted. '[The study's] findings make a strong case to explore the effect of therapies to lower Lp(a) in participants with PAD [peripheral artery disease] and carotid stenosis towards the goal of slowing disease progression and reducing major complications of amputation and stroke,' they added. SOURCE: This study was led by Tiffany R. Bellomo, MD, of Broad Institute of Harvard and MIT, Cambridge, Massachusetts. It was published online on July 28, 2025, in Circulation. LIMITATIONS: Measuring Lp(a) using immunoassays may be inaccurate for individuals with large Lp(a) isoforms. This study lacked measurement of ankle-brachial index to define peripheral arterial disease. The analysis may not have accounted for all potential confounding factors. DISCLOSURES: This study received grants from the National Heart, Lung, and Blood Institute and the National Human Genome Research Institute. One author reported receiving research grants and personal fees from several pharmaceutical and healthcare companies and holding equity in multiple healthcare data and biotech firms. The same author reported spousal employment at a pharmaceutical company. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Tensive appoints medical device veteran Bill Hunter Chairman as its bioresorbable scaffold for breast reconstruction after cancer approaches market
Tensive appoints medical device veteran Bill Hunter Chairman as its bioresorbable scaffold for breast reconstruction after cancer approaches market

Yahoo

timean hour ago

  • Yahoo

Tensive appoints medical device veteran Bill Hunter Chairman as its bioresorbable scaffold for breast reconstruction after cancer approaches market

Has more than 30 years of experience bringing innovations to market, including one of the world's first drug-eluting coronary stents at Angiotech Pharma Appointment adds world-class capabilities to Tensive as the company approaches pivotal clinical trial milestones Pivotal trial may enable European and U.S. commercialization of Tensive's innovative bioresorbable REGENERA™ and SOFTAG™ devices for breast reconstruction and tissue marking Tensive published positive first impressions from pivotal trial in April, and from first-in-human trial in 2023 Milan, Italy – August 5, 2025 – Tensive S.r.l, a clinical-stage advanced biomaterials medical device company, and the developer of REGENERA™ and SOFTAG™ bioresorbable scaffolds for breast reconstruction and tissue marking, has appointed Bill Hunter, MD, as Chairman of its Board of Directors. Dr. Hunter brings more than 30 years of leadership in the medical technology and life sciences sectors. His appointment reflects Tensive's focus on strengthening its governance and expanding its global network as it accelerates toward pivotal clinical milestones and commercialization in the U.S. and Europe. Dr. Hunter is the founder and CEO of Canary Medical, a medical data company developing implantable sensor technology. Previously, he founded Angiotech Pharmaceuticals, where he led the development of one of the world's first drug-eluting coronary stents, a multi-billion-dollar innovation that transformed interventional cardiology. 'It's a great honor and validation of the medical potential of Tensive's advanced biomaterials that Bill has accepted to lead our board of directors. His track record of successfully guiding pioneering technologies from concept to commercialization is unmatched,' said Sanjay Kakkar, Chief Executive Officer of Tensive. 'Bill's strategic insights and industry perspectives will be crucial advantages as we complete registrational studies and advance our first device into regulatory processes for marketing approval and commercialization in the U.S. and Europe.' Tensive's innovative polymeric bioresorbable scaffolds allow a natural, non-invasive, permanent and safe solution for breast reconstruction during lumpectomy. In addition, they enable precision tissue marking, demarcating the affected area to direct more targeted radiotherapy and improve imaging accuracy during surveillance and follow-up. 'I am truly excited to join Tensive at such a pivotal moment in its journey,' said Bill Hunter, MD, Chairman of the Tensive Board of Directors. 'In addition to being impressed by the leadership, I became convinced that this was an exceptional opportunity after reviewing the recently published interim data from the ongoing pivotal study of REGENERA™, as well as the excellent long-term follow-up data from the first-in-human clinical trial. The enthusiasm expressed by the key opinion leaders involved with the clinical studies further confirmed my impression of the data. I look forward to supporting Sanjay and his experienced team at Tensive as they bring REGENERA™ and SOFTAG™ to the market.' REGENERA™ / SOFTAG™ advanced biomaterial is a bioresorbable implant designed to be placed during lumpectomy surgery. The bioresorbable medical device is gradually absorbed by the body and enables the patient's own tissue to regrow in the area it fills. The result is breast restoration composed of natural tissue that preserves the patient's original breast shape and feel, yet is clearly differentiated from surrounding tissues on imaging, supporting more targeted delivery of radiotherapy and more accurate monitoring for potential recurrence. The biomaterial used in REGENERA™ and SOFTAG™ resembles a sponge with a fine scaffold matrix; its placement during the lumpectomy surgery is a one-step, minimally invasive, rapid and easy-to-adopt procedure. Currently, patients undergoing benign and malignant lumpectomy do not typically receive cosmetic intervention to prevent breast disfigurement, which can be psychologically devastating. Of the 2.1 million lumpectomies performed worldwide each year, 1.9 million are not reconstructed, constituting a sizeable unmet clinical need [1]. Despite the psychological impact of breast disfigurement following lumpectomy, more common cosmetic surgery options are rarely used, because they entail invasive and complex procedures that often fail to achieve the desired outcome. Preliminary data from the first 16 patients in Tensive's ongoing multi-center pivotal trial in 94 patients undergoing malignant lumpectomy were published in Updates in Surgery in April 2025, with investigators writing: 'In conclusion, we are convinced that REGENERA™ could represent a great innovation in breast oncological surgery, representing a possible alternative to volume replacement with faster operative time, faster recovery, less morbidity, and good patient satisfaction [2].' These results followed the publication in Breast Cancer in 2023 of six-month follow-up data from five patients in a first-in-human trial that demonstrated positive outcomes in terms of both safety and performance, leading the clinical investigators who authored the paper to conclude that the data were 'paving the way to an innovative approach with a potential remarkable impact on clinical application of tissue engineering [3].' [1] Analysis based on estimates from the International Society of Aesthetic Plastic Surgery (ISAPS), Breast Cancer Research Foundation (BCRF), the American College of Surgeons (ACS), the World Health Organization (WHO) and Global Market Insights.[2] A.V.E. Lisa et al. Updates in Surgery Apr 2025. Mariniello et al. Breast Cancer 2023. S.r.l. ( is a clinical-stage advanced biomaterials medical device company developing bioresorbable polymeric scaffolds for breast reconstruction and tissue marking. Its patented REGENERA™ biomimetic scaffold is designed to allow regeneration of a patient's own breast tissue to create natural, safe, and lasting reconstruction for patients recovering from lumpectomy or undergoing cosmetic procedures, while its SOFTAG™ precision tissue marking device enables more targeted delivery of radiotherapy and increases the accuracy of surveillance and follow-up. Tensive's mission is to improve clinical outcomes and the quality of life for women worldwide through accessible, innovative, and sustainable solutions. For more information please contact: Tensive Srl Cohesion Bureau media@ Italian and international media & investorsGiovanni Ca' Zorzitensive@ 7 8467 0727 Attachment 20250805 Tensive PR Bill Hunter appointment (final)Error in retrieving data Sign in to access your portfolio Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store